Navigation Links
Spherix Announces Positive Phase 2 Study Results
Date:6/24/2009

Preliminary Data Demonstrates Reduction of HbA1c Levels With Doses an Order of Magnitude Lower than the Dose Used in the Current Phase 3 Trial.

BETHESDA, Md., June 24 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced positive preliminary results from a Phase 2 clinical trial of its novel compound, Naturlose(R) (D-tagatose), in the treatment and management of Type 2 diabetes. The Phase 2 trial is expected to be completed in early 2010.

In the ongoing single-blind study designed to establish the minimum dose of Naturlose capable of causing a beneficial effect, Naturlose is administered orally with meals, three times daily (TID) at three different doses: 2.5, 5.0, and 7.5 g. The comparator is the 2.5 g dose. The primary endpoint for the study is reduction in HbA1c after 6 months on the drug. After 6 months on drug, the patients in the 7.5 g group experienced an average reduction of 0.3% in HbA1c from the HbA1c of the 2.5 g group. At that same 6-month point, the 5.0 g group averaged a reduction in HbA1c of 0.05% from the 2.5 g group. Naturlose appears to begin showing an effect on HbA1c within the range of doses selected for this minimum-dose study. The ongoing Phase 3 double-blinded study of efficacy is being conducted at a 15 g dose (TID), and is powered to detect a 0.5% reduction in HbA1c.

Over the course of the Phase 2 trial, Naturlose also decreased the average serum triglycerides of the patients by -59 mg/dl by the end of the first month on therapy, a decrease from baseline that remained at -41 mg/dl by the end of the 6 months of the trial. Naturlose also decreased serum LDL by an average -13 mg/dl by the end of the first month on therapy, while serum HDL was essentially unchanged (+0.9 mg/d
'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Spherix Reports First Quarter 2009 Earnings
2. Spherix Elects New Independent Director, and Elects Chairman of the Board
3. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Spherix D-tagatose to be Supplied by Inalco SpA
6. Growth Achieved in Spherixs Health Sciences Consulting Business
7. Spherix Reports Second Quarter Earnings
8. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
9. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
10. CoAxia, Inc. Announces $21.5M Series D Financing
11. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CHICAGO and SOUTH SAN ... -- The Pulmonary Fibrosis Foundation (PFF) and ... announced that the organizations are partnering on a ... diagnostic experiences with interstitial lung diseases (ILDs), including ... Patient Journey (INTENSITY) survey will assess the steps ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... the "Company"), a biopharmaceutical company focused on the development ... it will release its year-end financial results for the ... 4, 2015. DelMar,s management team will ... for investors, analysts and other interested parties on Friday, ...
(Date:8/27/2015)... August 27, 2015 The global ... reach USD 3.96 billion by 2022, according to a ... of chronic venous disorders such as deep vein thrombosis, ... serve as the key driver.      (Logo: ... injuries are also expected to boost market growth over ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from ... presented,strong evidence today that an antibiotic typically prescribed ... types of cancers. , Q. Ping Dou, Ph.D., ... lab announced the findings of their study showing,that ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ZIOPHARM ... of preclinical,data strongly supportive of the development ... demonstrates very high,bioavailability when administered orally; in ... well suited to oral,administration. These data were ...
Cached Medicine Technology:Alzheimer's Drug Shows Promise in Fighting Cancer 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 3
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... array of instruments available for quantitative PCR (qPCR) in the last ... higher throughput and reduced operating costs. On the flipside, where do lab managers, ...
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... 27, 2015 , ... The Naderi Center is proud to announce that its ... procedure to improve submental fat. The first and only Food and Drug Administration ... Dr. Kulak is the only Board Certified surgeon in the D.C., Maryland, Virginia area ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... CEL-SCI Corporation (NYSE AMEX: CVM ) announced today financial results ... results: , , ... of 41% compared to a net loss of $3,210,294 during the same quarter ... loss per common share for the quarter ended March 31, 2009 was $0.02 ...
... 15 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: ... quarter ended March 31, 2009. Amounts, unless specified ... accordance with Canadian Generally Accepted Accounting Principles (Canadian ... 2009, the exchange rate was CAD$1.00=US$0.7928.Results of OperationsWe ...
... PARIS, FRANCE The International Union for Health ... Health Education (SOPHE) are pleased to release today special, ... and quality assurance systems of global capacity in health ... Education & Behavior (Vol. 36, No. 3, June ...
... Help Employers and Business Owners Plan for Pandemic ImpactPLYMOUTH ... hosting two free webinars on May 19, 2009 to ... Following the webinar Health Advocate will release a special ... summarizing steps for employers to take.Two experts - ...
... May 15 Within weeks, the University of ... campus that will provide a springboard for new discoveries, ... wise investment for U-M,s future.U-M,s purchase of the former ... North Campus will be completed on June 16, said ...
... of Medicine (BUSM) have found a high frequency ... the largest neonatal intensive care units (NICUs) in ... methods could reduce the vast number of hospital ... in the journal Infection Control and Hospital ...
Cached Medicine News:Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 2Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 3Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 4Health News:CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results 5Health News:Cardiome Reports First Quarter Results 2Health News:Cardiome Reports First Quarter Results 3Health News:Cardiome Reports First Quarter Results 4Health News:Special journal issues released on global health promotion and health education 2Health News:Experts to Discuss Worksite Preparedness Measures During May 19th Pandemic Flu Webinars 2Health News:U-M Purchase of Former Pfizer Facility Nears Completion, Paving the Way For Research Expansion and Job Creation 2Health News:BUSM researchers find gram-negative rods in two Philippine neonatal intensive care units 2
Express Elyte Systems....
... 1650 has minimal requirements for ... 2 L/test), reagent consumption (as ... water consumption (25 L/hour) - ... universal rack handler facilitates continuous ...
Iron Total (TIBC) (Iron Buffer + Iron Color=Std.). An Automated analyzer test kits....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Medicine Products: